UBS has reiterated its 'Buy' rating for Sanofi, with a target price of 110 euros, ahead of the company's upcoming quarterly earnings report on October 25.
Analyst Jo Walton highlighted the need to evaluate the sustainability of Dupixent and the market reception of Beyfortus in the upcoming results.
Sanofi shares have shown a positive trend, currently trading around 101 euros on various exchanges, indicating a slight increase. The stock has experienced fluctuations, reaching a high of 119.65 euros and a low of 86.12 euros in the past year.
Investors are eagerly awaiting the quarterly figures to assess the future performance of these key products.